文献速递腹部CT

术前腹部增强CT肿瘤强化比率用于预测II期结肠癌复发风险

Tumor enhancement ratio on preoperative abdominal contrast-enhanced CT scan for predicting recurrence risk in stage II colon cancer.
PubMed 文献 · Abdom Radiol (NY) · 2022-02-11

本研究纳入282例II期结肠癌患者,按7:3随机分为训练集和验证集,基于术前腹部增强CT的肿瘤强化比率(TER)构建LASSO Cox模型预测复发风险。TER最佳截断值为1.83,高TER患者无病生存期更差;基于TER的模型预测复发风险的C-index在训练集为0.784、验证集为0.725,按复发风险评分(截断值1.75)重新分组后两组DFS差异显著。

要点

  • TER最佳截断值1.83,高TER患者无病生存期更差(训练集与验证集p均<0.001)。
  • 基于TER的模型预测复发风险C-index训练集0.784、验证集0.725。
  • 按复发风险评分截断值1.75重新分组后两组DFS差异显著(p均<0.001)。

核心结论

  • TER可作为II期结肠癌的高危特征,基于TER的模型为评估II期结肠癌复发风险提供了新方法。

研究设计与样本

  • 回顾性研究,纳入282例II期结肠癌患者,按7:3随机分为训练集和验证集,采用术前腹部增强CT计算TER,以LASSO Cox模型构建复发风险预测模型。

诊断标准与关键数值

  • TER由增强CT肿瘤最大衰减值除以最小衰减值计算。
  • TER最佳截断值为1.83,由时间依赖ROC曲线得出。
  • 复发风险评分截断值为1.75,据此将患者重新分为改良高危组和非高危组。
  • 模型预测复发风险的C-index在训练集为0.784,在验证集为0.725。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The identification of high recurrence risk stage II colon cancer patients was critical to adjuvant chemotherapy decision. However, current definition of high-risk features remains inadequate. This study aimed to construct a model for predicting recurrence risk based on tumor enhancement ratio (TER) on abdominal contrast-enhanced CT scan.

METHOD: 282 stage II colon cancer patients were included and randomly divided into training and validation sets in the ratio of 7:3. TER was calculated using maximum tumor attenuation value in contrast-enhanced CT scan divided by the minimum. Kaplan-Meier survival analyses were adopted to evaluate the prognostic value of variables. A model based on TER was built to predict recurrence risk through the LASSO Cox model. The recurrence risk score of patients was calculated based on this model.

RESULTS: The optimal cut-off value of TER was 1.83 derived from the time-dependent ROC (tdROC) curve. Patients with high-TER showed increasingly poorer disease-free survival (DFS) in both training (p < 0.001) and validation (p < 0.001) sets. A model was built based on TER demonstrated satisfactory performance to recurrence risk prediction (C-index: 0.784 in the training set and 0.725 in the validation set). Patients were regrouped into modified high-risk and non-high risk according to recurrence risk score (cut-off value: 1.75) and a significant DFS difference was observed (training set: p < 0.001; validation set: p < 0.001).

CONCLUSION: TER can serve as a high-risk feature of stage II colon cancer. And a model based on TER provided a new approach to assess recurrence risk of stage II disease.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Ye, Lu, Deng, et al. Tumor enhancement ratio on preoperative abdominal contrast-enhanced CT scan for predicting recurrence risk in stage II colon cancer. Abdom Radiol (NY). 2022. PMID: 35146573. doi:10.1007/s00261-022-03412-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。